LEVETIRACETAM TEVA ® 250 MG

Valsts: Izraēla

Valoda: angļu

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

LEVETIRACETAM 250 MG

Pieejams no:

TEVA PHARMACEUTICAL INDUST.LTD

ATĶ kods:

N03AX14

Zāļu forma:

TABLETS

Ievadīšanas:

PER OS

Ražojis:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Ārstniecības grupa:

LEVETIRACETAM

Ārstēšanas norādes:

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Autorizācija datums:

2009-09-01